{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-24-000011","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.000622+00:00","generated_at":"2026-06-02T05:54:49.570689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025","bullets":["Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.","Cash, cash equivalents and marketable debt securities totaled $10.5M as of Mar 31, 2024; expected to fund operations through Q1 2025.","Intends to initiate Phase 3 INVINCIBLE-3 Study in mid-2024: INT230-6 monotherapy vs SOC in soft tissue sarcoma, 333 patients, overall survival endpoint.","Intends to initiate Phase 2/3 INVINCIBLE-4 Study in mid-2024: INT230-6 + SOC in neoadjuvant triple negative breast cancer, endpoint pCR.","Over 30 sites screened for INVINCIBLE-3; contracts in process; Phase 3 clinical supplies released and shipped."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-24-000011","json":"https://secwatch.observer/filing/0001567264-24-000011.json","markdown":"https://secwatch.observer/filing/0001567264-24-000011.md","text":"https://secwatch.observer/filing/0001567264-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/0001567264-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/intensity-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:54:49.570689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12ac2c787756912e2d6bf7d1d484a7c1e650e8b4","claim":"INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.","evidence_excerpt":"On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/0001567264-24-000011-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"Net loss was $4.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}